oxytocin

Brand: Pitocin, Syntocinon

ISMP High Alert Prototype Drug
Drug Class: oxytocic agent
Drug Family: uterotonic
Subclass: synthetic posterior pituitary hormone
Organ Systems: endocrinereproductive

Mechanism of Action

Binds oxytocin receptors in the myometrium, activating phospholipase C and increasing intracellular calcium, causing uterine contractions. Increases frequency and strength of contractions. Also stimulates milk ejection reflex via action on mammary myoepithelial cells.

oxytocin receptor (OXTR) in myometriummyoepithelial cells in mammary gland

Indications

  • induction of labor at term
  • augmentation of labor (insufficient contractions)
  • prevention and treatment of postpartum hemorrhage
  • management of incomplete/inevitable abortion

Contraindications

  • fetal malpresentation (some)
  • placenta previa
  • prior classic uterine incision
  • contraindications to vaginal delivery

Adverse Effects

Common

  • uterine hyperstimulation (contractions too frequent/too long)
  • nausea
  • vomiting
  • fetal heart rate abnormalities

Serious

  • uterine rupture
  • hyponatremia (with excess IV fluid — antidiuretic effect at high doses)
  • fetal distress/asphyxia
  • hypotension (rapid IV bolus)
  • amniotic fluid embolism (rare)

Pharmacokinetics (ADME)

Absorption IV infusion; nasal spray for milk letdown
Distribution distributed to extracellular fluid
Metabolism plasma oxytocinase (oxytocinase enzyme) and hepatic metabolism
Excretion renal
Half-life 1–6 minutes
Onset immediate (IV)
Peak minutes
Duration 1 hour (after stopping infusion)
Protein Binding 30%
Vd 0.3 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
vasoconstrictors additive vasopressor effects; severe hypertension when given with vasoconstrictors major
prostaglandins additive uterotonic effect; risk of excessive uterine stimulation major

Nursing Considerations

  1. Administer via IV infusion pump ONLY; titrate rate in small increments every 20–40 minutes based on contraction frequency; never administer as a rapid IV bolus in labor (hypotension risk).
  2. Monitor uterine contractions (should not exceed 5 in 10 minutes), fetal heart rate, and maternal vital signs continuously.
  3. If uterine hyperstimulation occurs: stop infusion, position patient in left lateral decubitus, provide oxygen, notify provider.
  4. For postpartum hemorrhage: 10–40 units in 1L IV fluid at a rate sufficient to control uterine atony; monitor for hyponatremia with large volumes.

Clinical Pearls

  • Oxytocin is the single most common cause of preventable harm in obstetrics — overdose causes uterine tachysystole, uterine rupture, and fetal hypoxia; proper infusion pump management and continuous electronic fetal monitoring are mandatory.
  • At doses used for postpartum hemorrhage, oxytocin has significant antidiuretic (ADH-like) properties; large volumes of hypotonic IV fluids with high-dose oxytocin can cause life-threatening dilutional hyponatremia.

Safety Profile

Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required